# Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose

> **NCT03999996** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 365 (actual)

## Conditions studied

- Dengue Fever

## Interventions

- **BIOLOGICAL:** Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03999996
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-12
- **Primary completion:** 2024-05-25
- **Final completion:** 2024-05-25
- **Target enrollment:** 365 (ACTUAL)
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03999996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03999996, "Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03999996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*